Edesa Biotech (NASDAQ:EDSA) Downgraded to “Strong Sell” Rating by Wall Street Zen

Posted by on Aug 9th, 2026

Wall Street Zen cut shares of Edesa Biotech (NASDAQ:EDSA – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday morning.

Other equities research analysts have also issued research reports about the company. Brookline Capital Markets upgraded Edesa Biotech to a “strong-buy” rating in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Edesa Biotech in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Edesa Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Check Out Our Latest Stock Analysis on EDSA

Edesa Biotech Price Performance

Edesa Biotech stock opened at $5.27 on Friday. The stock has a market capitalization of $50.77 million, a price-to-earnings ratio of -3.93 and a beta of 1.08. Edesa Biotech has a 1-year low of $0.72 and a 1-year high of $20.32. The business has a fifty day moving average price of $6.41 and a 200-day moving average price of $6.23.

Edesa Biotech (NASDAQ:EDSA – Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.25). On average, equities research analysts anticipate that Edesa Biotech will post -1.66 earnings per share for the current fiscal year.

Institutional Trading of Edesa Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP purchased a new stake in Edesa Biotech during the 3rd quarter valued at about $36,000. State Street Corp purchased a new position in shares of Edesa Biotech in the fourth quarter worth about $27,000. Diadema Partners LP purchased a new position in shares of Edesa Biotech in the fourth quarter worth about $77,000. DRW Securities LLC acquired a new stake in shares of Edesa Biotech during the fourth quarter worth about $191,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Edesa Biotech during the first quarter worth about $2,946,000. Institutional investors and hedge funds own 5.50% of the company’s stock.

About Edesa Biotech

(Get Free Report)

Edesa Biotech, Inc is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials.

Featured Articles

Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.